Stefan Jellbauer

Written by Stefan Jellbauer

Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

In recent years, there is growing interest in alternative treatments for both inflammatory bowel disease and irritable bowel syndrome. Clinical trials are underway to test the potential of probiotics and their metabolic substrates, which are called prebiotics. The underlying principle is that the microbiome might be targeted by providing the metabolic fuel (prebiotics) needed for the growth and expansion of…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

In recent years, there is growing interest in alternative treatments for both inflammatory bowel disease and irritable bowel syndrome. Clinical trials are underway to test the potential of probiotics and their metabolic substrates, which are called prebiotics. The underlying principle is that the microbiome might be targeted by providing the metabolic fuel (prebiotics) needed for the growth and expansion of…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

The prevalence of Celiac Disease (CD) has increased in the U.S. in the past 35 years – its true prevalence actually doubled every 15 years. The main driver behind this multifactorial, complex disease seems to be the interplay between genes and gluten, but as evidenced by recent studies, there are additional factors driving this epidemic of CD. Quality and quantity…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

The prevalence of Celiac Disease (CD) has increased in the U.S. in the past 35 years – its true prevalence actually doubled every 15 years. The main driver behind this multifactorial, complex disease seems to be the interplay between genes and gluten, but as evidenced by recent studies, there are additional factors driving this epidemic of CD. Quality and quantity…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

Do specific microbiota determine levels of specific metabolites? How does the metabolite profile develop during establishment of the microbiome in infants? Can we assess an individual’s physiological state based on gut flora and metabolites? These questions are key to translating scientific findings related to intestinal metabolites in order to bring them to the clinic. The relatively new scientific field of…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

Do specific microbiota determine levels of specific metabolites? How does the metabolite profile develop during establishment of the microbiome in infants? Can we assess an individual’s physiological state based on gut flora and metabolites? These questions are key to translating scientific findings related to intestinal metabolites in order to bring them to the clinic. The relatively new scientific field of…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

An interesting translational symposium of the American Association of Gastroenterology (AGA) at this year’s Digestive Disease Week (DDW) in Washington, D.C., was entitled, “Gut Microbiome and Clinical Outcomes in Pediatrics”. Speakers in this session discussed the current evidence on how the gut microbiome is established at birth and influenced by host and environmental factors. They also presented evidence on the…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.

An interesting translational symposium of the American Association of Gastroenterology (AGA) at this year’s Digestive Disease Week (DDW) in Washington, D.C., was entitled, “Gut Microbiome and Clinical Outcomes in Pediatrics”. Speakers in this session discussed the current evidence on how the gut microbiome is established at birth and influenced by host and environmental factors. They also presented evidence on the…

Stefan Jellbauer
Stefan Jellbauer is a Field Application Scientist in the Biotech industry. Previously, he was an ORISE fellow at the Food Safety division of the FDA and a Postdoc in Manuela Raffatellu’s lab at University of California, Irvine, where he studied host-pathogen interactions and mucosal immunology. He obtained his PhD in 2010 from Ludwig-Maximilians University in Munich, Germany.